보건의료분야 공적개발원조 사업을 위한 한국형 의약품 통합관리플랫폼 모델

Abstract

Health Insurance Review & Assessment Service (HIRA) developed two national drug management systems, the Drug Utilization Review (DUR) and Korea Pharmaceutical Information System (KPIS), which have been successfully in operation since 2010. The two systems have drawn interest internationally, and many developing nations are aiming to model their respective national drug management systems after the DUR and KPIS. The drug management systems have the advantage of being applied regardless of the regional regulations or laws, compared to the National Health Insurance System. HIRA has designed a model named the “K-Style Drug Integrated Management Platform”, which contains the integrated features of the DUR and the KPIS. The model was designed to standardize and generalize functions for ensuring the proper use and distribution of the drugs. The most important feature of the K-Style Drug Integrated Management Platform is the functions and responsibilities of the DUR. One of the main roles of the DUR is the prevention of drug misuse; for instance, dispensing drugs, which may harm pregnant women or elder patients. Another prominent feature is the KPIS, whose role is to monitor the distribution of drugs across the country. Through the services provided by the KPIS, monitoring the process of manufacturing, importing, and distributing drugs is made possible. HIRA has also added the feature preventing infectious diseases to the model, as a result of the global issue, which is the coronavirus disease 2019 pandemic. The K-Style Drug Integrated Management Platform will be implemented on the HIRA cloud platform, so the users from various countries will be able to access the integrated drug management system and check the possibility of developing their national plans.